Espenal

Quick links to important sections

Espenal

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Espenal

Property Description
Active Ingredient Eperisone Hydrochloride
Form Oral Tablets, Injectable Solution
Pharmacological Class Central Muscle Relaxant
General Purpose Alleviation of muscle stiffness and spasms
Origin Synthetic Small Molecule

Espenal is the trade name for a pharmaceutical product whose active ingredient is Eperisone Hydrochloride, a compound classified and clinically recognized as a Central Muscle Relaxant. This synthetic small molecule is designed to address conditions involving muscle rigidity and involuntary spasms, functioning as a single-ingredient medicine. The classification as a central muscle relaxant indicates the medicine primarily exerts its therapeutic effect by modulating nerve signals within the central nervous system, specifically the spinal cord, rather than acting directly on the peripheral muscle fibers. This central mechanism helps to reduce the abnormal nerve signals that cause muscles to become excessively tense.


Therapeutic Role and Physical Forms of Espenal

The general therapeutic purpose of Espenal is to deliver relief from muscle stiffness and associated discomfort by mitigating excessive muscular rigidity. Its efficacy in reducing muscle hypertonia is a well-established property of Eperisone, meaning it helps to ease the heightened muscle tension often associated with pain and restricted movement. Espenal is typically supplied as Oral Tablets, often film-coated or sugar-coated, which facilitates consistent and non-invasive intake. Depending on regional clinical settings and availability, an Injectable Solution may also be utilized, offering an alternative route for parenteral administration of the active substance. The focus of this formulation is the systemic management of muscle over-activity in adult patient groups.

What side effects are possible with Espenal?

Possible Side Effects and Safety Information

The official regulatory safety profile for Espenal (Eperisone Hydrochloride) details adverse reactions classified by frequency and affected body system. This information is derived strictly from government regulatory documentation, such as national medicine agencies' prescribing information, and is presented in a non-advisory, factual manner.


System-Organ Classes and Common Effects

The most commonly reported adverse reactions are generally associated with the Nervous System (drowsiness, light-headedness, general malaise, or lassitude) and the Gastrointestinal System (nausea, vomiting, loss of appetite, abdominal discomfort, diarrhea, or constipation). Skin reactions, such as rash and itching (pruritus), are also frequently cited in regulatory reports.


Serious Adverse Reactions

Official labeling documents explicitly identify rare but severe adverse reactions that are categorized as initial symptoms of treatment. These serious adverse reactions include Shock and Anaphylactoid Symptoms, as well as severe mucocutaneous reactions such as Steven-Johnson syndrome and Toxic Epidermal Necrolysis (TEN).


Population-Specific Safety Notes and Restrictions

Regulatory information advises that caution be exercised when the medicine is used in patients with a pre-existing hepatic disorder (liver impairment). Safety has not been established for use in children, and use during pregnancy and lactation is generally discouraged unless benefits outweigh potential risks, as the drug may be excreted in breast milk.

Due to the potential for central nervous system effects like drowsiness and light-headedness, the official safety documentation includes restrictions: individuals are formally advised to avoid operating hazardous machinery or driving a car. The medicine is also strictly contraindicated in patients with a known history of hypersensitivity to Eperisone Hydrochloride.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Espenal (Eperisone Hydrochloride) is associated with documented clinical signs primarily affecting the central nervous system and gastrointestinal tract. Regulatory-aligned information notes that manifestations may include excessive sleepiness or somnolence, accompanied by symptoms such as nausea and vomiting.

Severe Manifestations and Outcomes

Overdose, especially high exposure, has been associated with severe, potentially life-threatening complications. These documented outcomes include serious neurological events such as seizures. Of particular clinical concern are effects on the cardiovascular system, which may manifest as QTc prolongation and, in reported cases, ventricular tachycardia. Additionally, apnea (cessation of breathing) has been observed in overdose scenarios. Infants and children represent a population with specific risk, as accidental ingestion has led to severe neurological and cardiac events in this age group.

Emergency Actions Required

Given the potential for severe and life-threatening effects, regulatory guidance dictates a specific course of action upon suspected overdose or accidental ingestion of an excessive amount. If more than the prescribed dose of Espenal is taken, the required action is to consult with your doctor or pharmacist immediately. This mandate ensures prompt assessment of potential toxicity, particularly concerning the risk of severe cardiac and neurological complications. Overdose management is typically symptomatic and supportive, as no specific antidote is known.

Therapeutic Uses of Espenal

What Espenal Treats: Main Uses and Benefits

Espenal is generally used across therapeutic domains where patients experience symptoms related to heightened physiological activity in the muscles, such as involuntary contractions and localized pain. It is commonly used to address conditions like low back pain, cervicobrachial syndrome, and shoulder periarthritis. The primary benefit is symptomatic relief, contributing to easing the overall symptom load of acute discomfort and assists with maintaining functional stability.

The medication is also applied across domains where additional symptomatic support is needed to manage chronic muscle stiffness and spasticity resulting from underlying central nervous system conditions. This includes significant hypertonia associated with sequelae of cerebrovascular diseases (e.g., stroke) or spinal conditions. Generally supports the easing of this chronic rigidity, which in turn contributes to easing patient discomfort and may support participation in physical rehabilitation efforts.

It is considered relevant for easing symptoms that interfere with daily functioning, specifically when muscle rigidity causes restricted range of motion or myotonia (delayed muscle relaxation). When applied in addressing these manifestations, it may assist with maintaining functional stability when symptoms are more noticeable, providing supportive relief when physical symptoms interfere with routine activities.

“The medication is used for managing distressing muscular manifestations and supports the patient during episodes of heightened discomfort.”


Quick Fact: Relief for Excessive Muscle Tightening

Espenal plays a role in managing symptoms linked to increased muscular activity, contributing to easing day-to-day comfort during symptomatic periods.

Regulatory References

  1. Japanese Drug Information Sheet (PMDA/Kusuri-no-Shiori)

Eligibility and Restrictions for Use

Who Can and Cannot Use Espenal?

The official eligibility profile for Espenal (Eperisone Hydrochloride) is strictly defined by regulatory documentation, which specifies populations permitted for use, those for whom use is restricted, and those absolutely prohibited from taking the medicine.

Eligibility and Exclusion Status

Status Population Group Official Regulatory Description
Allowed Adult Population Intended for use in adults for designated indications.
Contraindicated Hypersensitivity Prohibited in patients with a history of allergy to Eperisone Hydrochloride or any component.
Restricted Pregnant Women Not recommended unless therapeutic benefits are formally assessed to outweigh possible risks.
Restricted Breastfeeding Women Not recommended; patient should discontinue breast-feeding if treatment is necessary.
Not Established Pediatric Patients Not recommended for children or adolescents as safety and efficacy have not been established.
Caution Required Older Adults Use requires close monitoring and caution, often necessitating dose adjustments.
Caution Required Hepatic Disorders Must be administered with care to patients with liver function impairment, as the condition may be aggravated.

The medicine is principally reserved for the adult population who do not have a known hypersensitivity to the drug. Regulatory documents define restrictions for several groups, including those with impaired liver function and older adults, where special administration measures are mandated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Espenal is defined by its role as a substrate for the cytochrome P450 enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Co-administration with other medicines that affect these systems can alter the concentration of Espenal in the body, which requires specific management constraints.

Interacting Product Category Official Restriction/Constraint
Strong CYP3A4 Inhibitors Co-administration is contraindicated due to the expected significant increase in Espenal exposure.
Strong CYP3A4 Inducers Concomitant use is generally to be avoided, as it may cause a marked decrease in Espenal concentration, potentially limiting its effectiveness.
P-glycoprotein Modulators Co-administration with strong P-gp inhibitors (which increase exposure) or inducers (which decrease exposure) requires the use of caution and/or specific monitoring.
QTc-Prolonging Agents Concurrent administration with other medicinal products known to prolong the QTc interval is restricted due to the potential for additive pharmacodynamic effects.

These official regulatory statements establish a do-not-combine rule for strong CYP3A4 inhibitors, such as certain antifungal agents or HIV protease inhibitors. For moderate inhibitors and inducers of CYP3A4, official documentation mandates specific procedural constraints, including close patient monitoring, to ensure safe use. The restrictions involving QTc-prolonging agents address a shared risk with other medicinal product classes.

Mechanism of Action

The Mechanism of Partial mu-Opioid Receptor Agonism

Espenal's primary action involves its high-affinity, sub-maximal binding to the mu-opioid receptor (mu-OR) in the central nervous system (CNS). This interaction initiates a G-protein signaling cascade that achieves a partial, sub-maximal activation in key neuronal populations, resulting in the modulation of mu-opioid receptor activity within the CNS signaling pathways.

Cellular Cascade and Neurochemical Stabilization

This mu-OR activation leads to the inhibition of adenylyl cyclase and subsequent reduction in the secondary messenger cAMP levels within affected neurons. This molecular consequence occurs particularly in systems governing reward and motivation, modulating the magnitude of signaling within these specialized pathways.

Ceiling Effect and Respiratory Regulation

A critical feature of the mechanism is the ceiling effect, where increasing the dose beyond a certain point does not produce a proportionally greater biological effect. This inherent mechanistic constraint limits the maximum level of activation achieved and influences the regulatory centers in the brainstem responsible for respiration, causing the attenuation of respiratory drive to reach a maximum at a specific receptor occupancy.

Dosage and Administration Information

How Espenal is Used

Espenal, which contains the active ingredient Eperisone Hydrochloride, is administered primarily via the oral route as a tablet. The usage patterns are standardized based on the medicine’s official regulatory prescribing information, defining the specific dose, frequency, and administration context.


Standard Dosing and Administration

The most common dosage form for Espenal is the 50 mg oral tablet. The standard regimen for adults involves a total daily dose of 150 mg of Eperisone Hydrochloride. This total dose is routinely administered in three equal, divided doses throughout the day.

Administration Timing

Oral tablets must be taken after each meal (post-prandially). This explicit instruction dictates the proper scheduling of the three daily doses.


Procedural Instructions and Dose Adjustment

Usage Constraint Official Instruction
Dose Flexibility The dosage may be adjusted according to the patient's age and the severity of symptoms, requiring professional guidance to modify the daily total.
Missed Dose Protocol If a dose is missed, it should be taken as soon as possible, but the patient must not take a double dose to compensate if it is near the next scheduled time.
Older Adults Use requires caution, and a reduced dose may be necessary due to potential changes in physiological function.
Pediatric Use The safety and effectiveness of the medicine have not been established for use in children.

The overall use protocol requires consistent administration, dividing the prescribed daily dose equally and adhering strictly to the required post-meal timing, while allowing for professional adjustment based on the clinical status of the patient.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Espenal

Evidence for use in Acute Musculoskeletal Spasm with Low Back Pain

Research has primarily involved studies of adults experiencing muscle spasms and physical discomfort in the lower back. This area of study is typically addressed through short-term Randomized Controlled Trials (RCTs) and systematic reviews, where patients were closely observed over defined time intervals. These studies were used in research exploring how symptoms change over time, examining outcomes related to physical discomfort and functional outcomes reflecting daily functioning or activity level.

Reports from short-term trials described patterns in measured outcomes, such as those in pain scores and indices of muscle tension, over the study period. However, these trials were primarily relevant in trials assessing short-term or episodic symptom patterns, meaning that the follow-up durations were limited, often lasting only two to four weeks.

Evidence for use in Cervicobrachial Syndrome and Spasticity

Evidence for stiffness in the neck and shoulder area (cervical spondylosis) and chronic muscle rigidity (spasticity, such as after a stroke) includes data from comparative trials. For cervical stiffness, studies examined outcomes related to physical discomfort and the range of motion in the neck. For chronic spasticity, research examined outcomes related to systemic or functional imbalance, such as changes in muscle reflex scores and certain parameters of walking capability.

For these conditions, the evidence quality varies across studies, and data show patterns related to temporary physiological imbalance rather than long-term functional stability. This means the research highlights what is known about short-term symptom patterns, but does not extensively cover sustained outcomes.

What is Still Uncertain About Espenal Research

The official scientific literature notes several gaps where additional research is needed. One key limitation is that comparative evidence is lacking for many potential scenarios, meaning direct head-to-head trials against all relevant active medicines are not uniformly available. Furthermore, certainty remains limited for many aspects of long-term use, particularly for chronic conditions characterized by functional limitations. The available evidence contributes to the broader evidence landscape but highlights what is known and what is still uncertain. Research provides context on group findings, and personal outcomes may vary.

Key Studies & References

  1. The effect of Eperisone on spinal function and paraspinal muscle blood flow in patients with chronic low back pain.

Frequently Asked Questions (FAQ)

Common questions about Espenal (FAQ)


Q: How long does it typically take to start noticing a change after taking Espenal?

Studies on how the body processes the medicine, known as pharmacokinetics, indicate that the active substance reaches its maximum concentration in the bloodstream relatively quickly, typically within approximately half an hour to two hours after a single dose. Official information notes that the medicine is also eliminated from the body fairly quickly, which influences the required administration schedule.


Q: Is Espenal the same type of drug as other common medicines for the same condition?

Espenal is officially classified as a Central Muscle Relaxant. The official classification indicates that its primary effect comes from modulating nerve signals within the central nervous system (CNS), specifically the spinal cord. This mechanism is a key factor that differentiates it from other medicinal products that may address similar conditions.


Q: What happens if I miss a dose of Espenal?

If a dose is missed, regulatory instructions state it is to be taken as soon as possible. However, the protocol indicates that a double dose must not be taken to compensate if it is nearly time for your next scheduled dose. This rule is in place to manage the concentration of the medicine in the body.


Q: Are there any foods or drinks I should avoid while using Espenal?

Official patient information indicates that the use of alcohol is to be avoided while taking this medicine. This is because the combination may lead to excessive drowsiness or other central nervous system effects. Beyond alcohol, no specific foods are listed as strictly restricted in official regulatory guidance.


Q: Is the evidence for Espenal's effectiveness strong?

Clinical trial summaries describe patterns in outcomes, primarily for short-term use in specific conditions like muscle spasms. Official scientific literature highlights that comparative evidence is lacking for many potential scenarios. Furthermore, certainty remains limited regarding many aspects of long-term use.


Q: What is the risk of a serious allergic reaction to Espenal?

Official documents explicitly identify severe reactions, such as Shock and Anaphylactoid Symptoms, as rare but severe adverse reactions. These events are classified as uncommon but potentially serious initial symptoms of treatment, and specific statistical frequencies are not always provided in patient-facing summaries.


Q: Is it necessary to take Espenal at a specific time of day?

Official administration guidelines state that the oral tablets are to be taken after each meal (post-prandially). This explicit timing is required for the proper spacing and scheduling of the total daily dose as described in the regulatory information.


Q: Why do some people report feeling tired after taking Espenal?

Official safety documents list effects on the Nervous System as commonly reported adverse reactions. These reactions include feelings like drowsiness, light-headedness, general malaise, or lassitude (a feeling of weariness), which are associated with the medicine's central mechanism of action.


Q: Will Espenal cure my condition or just help manage symptoms?

The general therapeutic purpose of Espenal is described as delivering relief from muscle stiffness and associated discomfort by mitigating excessive muscular rigidity (tension). Official information focuses on its role in symptom alleviation and management rather than making claims about curing the underlying condition.


Q: What should I tell my dentist or other doctors about Espenal?

Regulatory guidance indicates the importance of informing all healthcare professionals, including dentists, that the medicine is being taken. This helps them accurately assess any potential drug interactions with other prescribed treatments or manage known side effects, such as drowsiness, during procedures.


Q: Is Espenal available over the counter in some countries?

The regulatory status of the medicine varies depending on the country. In several major markets, Espenal is categorized as a prescription-only medicine (POM), meaning it legally requires a doctor’s order or prescription for dispensing.


Q: Is there a link between Espenal and changes in mood?

Adverse reaction reports list Psychoneurotic effects, which can include symptoms like insomnia and headache. Specific mood changes, such as anxiety or depression, are not consistently detailed among the common side effects in the official patient-facing regulatory documents.


Q: What are the different strengths or forms of Espenal available?

Espenal is supplied in two main forms. The most common is the Oral Tablet (often 50 mg strengths), which is taken by mouth. It is also available as an Injectable Solution for use in clinical settings, though tablet usage is generally the focus for ongoing patient treatment.


Q: Is Espenal generally considered safe for the average person?

Regulatory approval is granted when the drug’s anticipated therapeutic benefits are determined to outweigh its possible risks for its designated use in the intended population. However, the medicine is contraindicated in patients with a known history of hypersensitivity or allergy to the drug.


Q: Are generic versions of Espenal considered equivalent by regulatory bodies?

Yes, regulatory agencies require that any generic version of Espenal demonstrate bioequivalence to the brand-name product. This means the generic must be proven to deliver the active ingredient, Eperisone Hydrochloride, into the bloodstream at the same rate and to the same extent as the original product.

How should Espenal be stored and disposed of?

Storage Requirements

The official labeled storage conditions for Espenal (Eperisone Hydrochloride) tablets require the product to be maintained in an environment that controls for temperature and environmental exposure.

Storage Factor Official Requirement
Temperature Store at a temperature not exceeding 30 C in a cool place
Protection Must be protected from light and moisture, and kept away from direct sunlight and heat
Child Safety Mandatory to keep out of the reach of children and in a secure place
Stability Rule Any remainder of the product must be discarded and not stored after use

Disposal Instructions

All disposal of unused or expired Espenal must adhere to environmental protection standards and local regulations. The medicine must not be thrown away via wastewater or household waste. Patients should consult a pharmacist or utilize a drug take-back program for the proper disposal of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Espenal found in:

A-Z Index: